Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer

Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC). pCR in this setting is associated with improved EFS. Whether NCT pr...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Palmieri, Carlo, Macpherson, Iain RJ, Yan, Kelvin, Ades, Felipe, Riddle, Pippa, Ahmed, Riz, Owadally, Waheeda, Stanley, Barbara, Shah, Deep, Gojis, Ondrej, Januszewski, Adam, Lewanski, Conrad, Asher, Rebecca, Lythgoe, Daniel, de Azambuja, Evandro, Beresford, Mark, Howell, Sacha J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2015
Soggetti:
Clinical Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4914352/
https://ncbi.nlm.nih.gov/pubmed/26334099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.4801
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi